Mechanistic Insights into Cytokine Antagonist-Drug Interactions: A Physiologically Based Pharmacokinetic Modelling Approach with Tocilizumab as a Case Study
<b>Background:</b> Understanding interactions between cytokine antagonists and drugs is essential for effective medication management in inflammatory conditions. Recent regulatory authority guidelines emphasise a systematic, risk-based approach to evaluating these interactions, underscor...
Saved in:
| Main Authors: | Xian Pan, Cong Liu, Felix Stader, Abdallah Derbalah, Masoud Jamei, Iain Gardner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/7/896 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial
by: Abdallah Derbalah, et al.
Published: (2025-05-01) -
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01) -
PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01) -
Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01) -
Clinical efficacy and safety of tocilizumab in the treatment of seropositive rheumatoid arthritis patients in India
by: Abhishek Kumar, et al.
Published: (2020-01-01)